TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Resveratrol in Type2 Diabetes and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 years of age and older~2. Healthy Obese subjects with BMI \> 30~3. Type 2 Diabetics with BMI \> 30~4. Subjects with good peripheral vein.~5. Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study.~Exclusion Criteria:~1. Subjects on any antioxidant medication~2. Patient on non-steroidal anti-inflammatory drug~3. On any agent with significant antioxidant properties.~4. History of drug or alcohol abuse~5. Any life threatening disease~6. Allergy to peanuts, grapes, wine, mulberries.~7. Pregnant women.~8. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks.~9. Subjects on anticoagulants.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets
- Resveratrol 40 mg oral three times a day (Type: EXPERIMENTAL): Resveratrol
- resveratrol 500 mg oral once daily. (Type: EXPERIMENTAL): Resveratrol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spondyloarthritis positive for the ASAS criteria, treated with a first biologic : infliximab ( 5mg/kg intravenously every 8 weeks) or adalimumab (40mg subcutaneously every 2 weeks)~* Active spondyloarthritis definite by ASDAS-CRP \> 2.1 at two successive evaluations while patient was previously responder (ASDAS\<2.1 at least once in the 6th months after beginning of treatment)~* Positivity to anti-drug antibodies (ADAb)~* Consent of the patient~* No contra-indication to another anti-tnf biologic~* affiliation to health insurance~* woman of childbearing age must use an appropriate mean of contraception~Exclusion Criteria:~* Pregnant or breastfeeding woman~* contra-indication to anti-tnf biologic~* patient with known hypersensitivity to any of the excipients~* Severe and uncontrolled opportunistic infection , includins septicemia, tuberculosis, abcess and opportunistic infection~* Evolutive infection, including chronic or localised infection~* Patient with moderate to severe heart failure (NYHA class III/IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- early switch (Type: EXPERIMENTAL): * early switch of monoclonal antibodies anti-TNF~* anti drug antibodies dosage
- therapeutic intensification (Type: EXPERIMENTAL): * therapeutic intensification of monoclonal antibodies anti-TNF~* anti drug antibodies dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed diagnosis of Andersen-Tawil Syndrome, as defined by at least two of the following three features:~  1. Neuromuscular Feature~     * Presence of clear-cut episodes of transient muscle weakness with or without a fixed deficit that is typical with rest after exertion or prolonged rest, OR~    * An atypical history with specific exam findings (absent reflexes with normal sensation ictally), OR~    * Unexplained intraictal hypokalemia, OR~    * An abnormal nerve conduction exercise test~ 2. Cardiac Feature~     * Prolonged QTc interval on 12-lead electrocardiogram (ECG), according to standard criteria, AND/OR~    * Ventricular ectopy, including uniform or multifocal PVCs, polymorphic VT, or bidirectional VT~ 3. Physical Feature (at least two of the below five features)~     * Low set ears~    * Hypertelorism~    * Small mandible~    * Clinodactyly~    * Syndactyly~    * Micromelia of hands or feet~-OR-~* One of the three above criteria, with at leat one other family member meeting two criteria~-OR-~* Not meeting clinical criteria but possessing the KCNJ2 mutation~* An average frequency of at least one neuromuscular symptom (attack of weakness) per week~Exclusion Criteria:~* Sulfa allergy~* Renal impairment, as defined by serum creatine greater than 1.5 mg/dl~* History of renal calculi~* Cardiac disease or other disease that would make potassium supplementation or acetazolamide treatment inadvisable~* Diabetes mellitus~* Currently taking quinidine~* Pregnant

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has histological diagnosis of cancer of the endometrium of any histology or grade.~* The patient should have received no prior treatment for her endometrial cancer.~* The patient has clinically uterine confined disease.~* The patient is a candidate for minimal invasive surgery, with sentinel lymph node assessment with IC-GREEN planned as part of standard of care.~* The patient has an Eastern Cooperative Group (ECOG) performance status of 0-2.~* If age less than or equal to 55 years, the patient has a negative pregnancy test within 72 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.~* The patient has provided written informed consent.~* The patient is at least 18 years of age at the time of consent~Exclusion Criteria:~* The patient has clinical or radiological evidence of metastatic disease.~* The patient has a history of a prior loop electrosurgical excision procedure (LEEP) or cone procedure performed on her cervix.~* The patient has participated in another investigational drug study within 30 days of scheduled surgery.~* The patient has an iodine allergy.~* The patient is pregnant or lactating.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lymphoseek/SPECT-CT/Indocyanine (Type: EXPERIMENTAL): The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Multiple Concussions in Retired NHL Players

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Retired professional NHL player~* History or reported concussion and concussion like symptoms~Exclusion Criteria:~* Any neurological condition~* Non sport related head trauma

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Case / Retired NHL Players (Type: None): All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers
- Age Matched Controls (Type: None): All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* polymerase chain reaction (PCR) confirmed COVID-19~* severe stage of pneumonia caused by SARS-CoV-2 requiring oxygen therapy~* informed consent to participate in the study~Exclusion Criteria:~* qualification to palliative care~* life expectancy \< 48 h~* mechanical ventilation at the beginning of the hospitalization~* transfer from other ICU~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neuromuscular symptoms due to the A3243G mitochondrial DNA point mutation~* PCR/ATP ratio of \<1.9 following the Cardiac MRS at screening~Exclusion Criteria:~* Any major illness not due to the A3243G mitochondrial DNA point mutation in the past three months or any significant ongoing chronic medical illness, especially significant central nervous neurological disease limiting capacity to carry out the study~* Use of any investigational product within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A0001 (Type: EXPERIMENTAL): A0001 (0.75 g BID)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must demonstrate willingness to participate in the study and to be compliant with any protocol procedure.~* Provision of written informed consent prior to any study related procedure.~* Diagnosis of an inoperable malignant bowel obstruction, confirmed by appropriate imaging report.~* In case of peritoneal carcinomatosis, diagnostic confirmation by CT or MRI scan.~* Confirmed as inoperable after medical advice.~* Patient with a nasogastric tube or presenting with 3 or more episodes of vomiting every day in the last consecutive 48 hours.~* Patient life expectancy must be more than 14 days.~Exclusion Criteria:~* Has operable obstruction or any sub-obstruction.~* Has bowel obstruction due to a non-malignant cause; (hypokaliaemia, drug side-effects, renal insufficiency, etc).~* Has signs of bowel perforation.~* Has prior treatment with somatostatin or any analogue within the previous 60 days.~* Has a known hypersensitivity to any of the study treatments or related compounds.~* Is likely to require treatment during the study with somatostatin or any analogue other than the study treatment.~* Is at risk of pregnancy or lactation, or is likely to father a child during the study. Females of childbearing potential must provide a negative pregnancy test at start of study and must be using oral or double barrier contraception. Non childbearing potential is defined as post-menopause for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study.~* Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.~* Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care and Lanreotide Autogel (Type: EXPERIMENTAL): Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
- Standard care (Type: NO_INTERVENTION): Standard care according to site clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on Systemic and Airway Cytokines and Oxidative Stress in Lung Cancer Patients Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed early-stage non-small cell lung cancer undergoing curative surgical lung resections.~* Life expectancy \> 12 weeks.~Exclusion Criteria:~* Respiratory failure requiring use of supplemental oxygen therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lung cancer (Type: None): Non-small cell lung cancer patients undergoing surgical lung resections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have been treated with a stable dose of metformin for at least 3 months and have been treated with an optimally effective and stable dose of an sulfonylurea for at least 6 months prior to screening.~* HbA1c value between 7.0% and 10.0%, inclusive.~* Body mass index (BMI) between 20 and 45 kilograms/square meter (kg/m\^2), inclusive.~Exclusion Criteria:~* Known type 1 diabetes mellitus.~* More than 1 episode of severe hypoglycemia within 6 months prior to screening.~* Two or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.~* Severe gastrointestinal disease that may significantly impact gastric emptying or motility or having undergone gastric bypass or gastric banding surgery.~* Previous history or active diagnosis of pancreatitis.~* Positive hepatitis B surface antigen or hepatitis C antibody.~* Clinical signs or symptoms of liver disease, or hepatic aminotransferases (aminotransferase or alanine aminotransferase) greater than 2.0× upper limit of normal (ULN) or elevated alkaline phosphatase (greater than ULN) unrelated to bone metabolic disease.~* Elevated total bilirubin level (greater than ULN), clinically suspicious signs/symptoms of cirrhosis or history of cirrhosis.~* Current diagnosis, personal history of neuroendocrine tumors, family history of any type of multiple endocrine neoplasia (MEN), or Von Hippel-Lindau.~* Contraindications for magnetic resonance imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- LY2409021 (Type: EXPERIMENTAL): 20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
- Sitagliptin (Type: ACTIVE_COMPARATOR): 100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~* Diagnosis of engraftment failure either primary or secondary, following allogeneic transplantation. Graft failure is defined as absolute neutrophil count \< 500/mm3 and/or platelet count \< 20,000/mm3. Primary graft failure is defined as failure to maintain absolute neutrophil count \> / = 500/mm3 for 3 consecutive days following allogeneic transplantation. Secondary graft failure is defined as failure to sustain an absolute neutrophil count \> / = 500/mm3 after attainment of primary engraftment or failure to sustain platelet count \> / = 20,000/mm3 despite neutrophil engraftment. For SCID patients, graft failure is defined as failure to recover \> / = 500/mm3 T-cells and/or failure to generate satisfactory response to in vitro mitogen stimulation. For patients with genetic diseases, engraftment failure is defined as donor chimerism insufficient to correct or overcome the genetic or metabolic deficiency.~* Available Healthy Donor without any contraindications for donation (5/6 or 6/6 related donor or 5/6 or 6/6 unrelated donor (molecular typing for DRB1)~* Age between birth and 65~* For women of childbearing potential, negative pregnancy test~EXCLUSION CRITERIA~* Pregnant and lactating women or women unwilling to use contraception.~* Uncontrolled intercurrent infection~* Refractory AML or ALL~* Untreated Blast Crisis for CML~* Uncontrolled High-grade lymphoproliferative disease/lymphoma~* Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)~* Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)~* Hemodialysis dependent~* Active Hepatitis or cirrhosis with total bilirubin, SGOT, or SGPT greater than 3 x normal.~* Concurrent solid organ malignancy not in remission, except for Stage 0 or A prostate cancer.~* Unstable Cerebral vascular disease and recent hemorrhagic stroke (less than 6 months)~* Active CNS disease from hematological disorder.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues